The clinical trial conducted by Rhode Island Hospital investigates the efficacy of sertraline, a selective serotonin reuptake inhibitor (SSRI), in treating psychogenic nonepileptic seizures (NES) associated with comorbid psychiatric disorders such as depression, anxiety, and PTSD. Given the increasing recognition of the psychological underpinnings of NES, this trial addresses a niche yet significant market. If successful, sertraline could be positioned as a first-line treatment option, potentially leading to a competitive advantage in the psychiatric and neurology markets. The results may also support further funding for larger-scale trials, enhancing the commercial viability of sertraline in this indication.